Zomedica (ZOM) investor relations material

Market opportunity and business overview

• Addressable market exceeds $2.7 billion annually, with six proprietary technology platforms targeting veterinary care.

• Animal health market in the U.S. is over $62 billion and growing, with increased pet ownership post-COVID.

• Revenue has grown for eighteen consecutive quarters, reaching $27 million last year, with 14% year-over-year growth in Q2.

• International sales account for 20% of revenue, with 13% growth last quarter.

• Company holds $59 million in liquidity, supporting ongoing growth and profitability goals.

Product portfolio and innovation

• PulseVet shockwave system is the top revenue generator, offering recurring revenue through consumable handpieces.

• Assisi Loop provides targeted electromagnetic therapy, with about a third of revenue from reorders.

• Vetagel Hemostatic Gel stops bleeding rapidly and is distributed in the U.S. since January.

• TrueView digital microscope launches AI-generated reports this quarter, with a subscription-based model.

• TruForm diagnostics platform uses advanced sensors, offering 15 assays and a pay-per-use cartridge model.

Commercial strategy and operations

• Direct U.S. sales force covers 36 territories, supported by clinical and management teams.

• Online channels like Chewy and pet.com drive direct-to-consumer sales, especially for Assisi Loop.

• Manufacturing is fully integrated in U.S. facilities, with scalable capacity and stable supply chain.

• No further major investment needed for manufacturing; facilities can support significant revenue growth.

• Gross margins range from 67% to 70%, with expectations to improve as volume increases.